Acide 2-nitro-3,5-dimethoxybenzoique | 113884-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Acide 2-nitro-3,5-dimethoxybenzoique
• 英文别名: 3,5-dimethoxy-2-nitrobenzoic acid；3,5-dimethoxy-2-nitro-benzoic acid；2-Nitro-α-resorcylsaeure-dimethylaether；3,5-Dimethoxy-2-nitro-benzoesaeure
• CAS: 113884-71-2
• 化学式: C₉H₉NO₆
• 分子量: 227.174
• InChiKey: UNEDSISIPFONDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Acide 2-nitro-3,5-dimethoxybenzoique 在 盐酸 、 氯化亚砜 、 氢碘酸 、 三乙胺 、 tin(ll) chloride 作用下， 以 乙醚 、 二氯甲烷 、 水 、 苯 为溶剂， 反应 4.0h， 生成 2-amino-3,5-dimethoxyacetophenone
  参考文献：
  名称：

  Roblot, Francois; Hocquemiller, Reynald; Cave, Andre, Journal of Chemical Research, Miniprint, 1989, # 11, p. 2637 - 2651

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl 3,5-dimethoxy-2-nitrobenzoate 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 0.5h， 以87%的产率得到Acide 2-nitro-3,5-dimethoxybenzoique
  参考文献：
  名称：

  对映体纯circumdatins E，H和J的简明合成†

  摘要：

  对映纯环丁E的简明全合成， H和J是通过手性N-脯氨酰基-2-硝基苯甲酰胺的还原环化反应构建的喹唑啉酮 戒指。

  DOI：

  10.1039/b925494c

文献信息

• 2-ureido-benzamide derivatives
  申请人：Grelan Pharmaceutical Co. Ltd.

  公开号：US05872115A1

  公开（公告）日：1999-02-16

  This invention is concerned with 2-ureido-benzamide compounds of the formula (1) ##STR1## in which R.sup.1 is H, halogen atom, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy or (C.sub.1 -C.sub.4)dialkylamino and R.sup.2 is H, halogen atom, hydroxy, nitro, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, (C.sub.3 -C.sub.6) cycloalkylmethoxy, (C.sub.1 -C.sub.4) alkylthio, (C.sub.1 -C.sub.4) alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or ##STR2## wherein j is an integer of from 0 to 2 and R.sup.3 and R.sup.4 are each independently H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkanoyl, (C.sub.1 -C.sub.4)alkylsulfonyl or (C.sub.1 -C.sub.4)alkylcarbamoyl, NR.sup.3 R.sup.4 can to form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring; X is a (C.sub.3 -C.sub.15)alkyl, (C.sub.3 -C.sub.6) cycloalkyl, (C.sub.3 -C.sub.6) cycloalkylmethyl, .omega.-(C.sub.1 -C.sub.4) alkoxy-(C.sub.1 -C.sub.4) alkyl group or ##STR3## wherein k is an integer of from 1 to 4 and R.sup.5 and R.sup.6 are each independently H, Y is H or (C.sub.1 -C.sub.4)alkyl and Z is ##STR4## wherein m is an integer of from 0 to 4.

  本发明涉及式（1）的2-尿素基苯甲酰胺化合物 其中R1为H，卤素原子，（C1-C4）烷基，（C1-C4）烷氧基或（C1-C4）二烷基氨基，R2为H，卤素原子，羟基，硝基，（C1-C4）烷基，（C1-C4）烷氧基，（C3-C6）环烷基甲氧基，（C1-C4）烷硫基，（C1-C4）烷基亚磺酰基，（C1-C4）烷基磺酰基或式（2） 其中j为0至2的整数，R3和R4各自独立地为H，（C1-C4）烷基，（C1-C4）酰基，（C1-C4）烷基磺酰基或（C1-C4）烷基氨基甲酰基，NR3R4可以形成吡咯烷，哌嗪，吗啉，咪唑或吡唑环；X为（C3-C15）烷基，（C3-C6）环烷基，（C3-C6）环烷基甲基，ω-（C1-C4）烷氧基-（C1-C4）烷基或式（3） 其中k为1至4的整数，R5和R6各自独立地为H，Y为H或（C1-C4）烷基，Z为式（4） 其中m为0至4的整数。
• 2-Ureido-benzamide derivatives
  申请人：GRELAN PHARMACEUTICAL CO., LTD.

  公开号：EP0742208A1

  公开（公告）日：1996-11-13

  This invention relates to 2-ureido-benzamide compounds of the formula : in which R1 is H, halogen atom, (C1-C4)alkyl, (C1-C4)alkoxy or (C1-C4)dialkylamino and R2 is H, halogen atom, hydroxy, nitro, (C1-C4)alkyl, (C1-C4)alkoxy or -(CH2)jNR3R3, wherein j is an integer of from 0 to 2, R3 and R4 are each independently H, (C1-C4)alkyl, (C1-C4)alkylsulfonyl or (C1-C4)alkylcarbamoyl, or R3 and R4 taken together with the N-atom to which they are linked can form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring ; X is a (C3-C15)alkyl or -(CH2)kNR5R6 group, wherein k is an integer of from 1 to 4 and R5 and R6 are each independently H, (C1-C6)alkyl or (C1-C4)alkoxycarbonyl ; and, Y is H or (C1-C4)alkyl and Z is or -(CH2)m―A2 wherein m is an integer of from 0 to 4, Q is -CH2- or -CH2CH2-, A1 is phenyl, benzyl, diphenylmethyl, pyridyl, imidazolyl, imidazolythio, dibenzoxepinyl or phenoxycarbonyl optionally carrying halogen atom, hydroxy, (C1-C7)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxymethyl, phenyl or halogenophenyl, A2 is phenyl, benzyl, diphenylmethyl, imidazolylthio, dibenzoxepinyl or phenoxycarbonyl optionally carrying halogen atom, hydroxy, (C1-C7)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxymethyl, phenyl or halogenophenyl, R7 is H or (C1-C4)alkyl and R8 is (C1-C4)alkyl, or R7 and R8 taken together with the C-atom to which they are linked can form a cyclopentyl, cyclohexyl or cycloheptyl ring ; or, Y and Z taken together with the N-atom to which they are linked can form a ring wherein n is an integer of from 1 to 3 and B is phenyl, diphenylmethyl or dibenzocycloheptenyl optionally carrying halogen atom or (C1-C4)alkoxy ; and pharmaceutically acceptable acid addition salts thereof. Those compounds are useful as acyl-CoA:cholesterol acyltransferase inhibitors.

  本发明涉及式.的 2-脲基苯甲酰胺化合物： 其中 R1 是 H、卤素原子、(C1-C4)烷基、(C1-C4)烷氧基或 (C1-C4)二烷基氨基，R2 是 H、卤素原子、羟基、硝基、(C1-C4)烷基、(C1-C4)烷氧基或 -(CH2)jNR3R3，其中 j 是 0 至 2 的整数、R3 和 R4 各自独立地为 H、(C1-C4)烷基、(C1-C4)烷基磺酰基或(C1-C4)烷基氨基甲酰基，或 R3 和 R4 与它们连接的 N 原子一起可形成吡咯烷、哌啶、吗啉、咪唑或吡唑环； X 是(C3-C15)烷基或-(CH2)kNR5R6 基团，其中 k 是 1 至 4 的整数，R5 和 R6 各自独立地是 H、(C1-C6)烷基或(C1-C4)烷氧羰基；以及 Y 是 H 或 (C1-C4) 烷基，Z 是 或-(CH2)m-A2 其中，m 是 0 至 4 的整数，Q 是-CH2-或-CH2CH2-，A1 是苯基、苄基、二苯甲基、吡啶基、咪唑基、咪唑硫基、二苯并氧杂环庚基或苯氧羰基，可选择带有卤素原子、羟基、(C1-C7)烷基、(C1-C4)烷氧基、(C1-C4)烷氧基甲基、苯基或卤素苯基，A2 是苯基、苄基、二苯甲基、咪唑硫基、二苯并氧杂环庚基或苯氧羰基、R7 是 H 或 (C1-C4)烷基，R8 是 (C1-C4)烷基，或 R7 和 R8 与它们连接的 C 原子一起可形成环戊基、环己基或环庚基环；或 Y 和 Z 与它们连接的 N 原子一起可形成一个环 其中 n 为 1 至 3 的整数，B 为苯基、二苯甲基或二苯并环庚烯基，可选择携带卤素原子或（C1-C4）烷氧基；及其药学上可接受的酸加成盐。 这些化合物可用作酰基-CoA：胆固醇酰基转移酶抑制剂。
• Insole, Joan M., Journal of Chemical Research, Miniprint, 1990, # 12, p. 2831 - 2867
  作者：Insole, Joan M.

  DOI：——

  日期：——
• [EN] TERTIARY AMIDES AND METHOD OF USE<br/>[FR] AMIDES TERTIAIRES ET PROCÉDÉ D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2017177004A8

  公开（公告）日：2017-11-30
• Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1<i>H</i>-benzimidazole (ZSTK474)
  作者：Gordon W. Rewcastle、Swarna A. Gamage、Jack U. Flanagan、Raphael Frederick、William A. Denny、Bruce C. Baguley、Philip Kestell、Ripudaman Singh、Jackie D. Kendall、Elaine S. Marshall、Claire L. Lill、Woo-Jeong Lee、Sharada Kolekar、Christina M. Buchanan、Stephen M. F. Jamieson、Peter R. Shepherd

  DOI：10.1021/jm200688y

  日期：2011.10.27

  A structure activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474) identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivatives. The 6-amino-4-methoxy analogue displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy analogue against all three class Ia PI 3-kinase enzymes (p110 alpha, p110 beta, and p110 delta) and also displayed significant potency against two mutant forms of the p110 alpha isoform (H1047R and E545K). This compound was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Ragl(-/-) mice, and at a dose of 50 mg/kg given by ip injection at a qd x 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.